Novartis disclosed seven previously unknown tumor cases in children treated with Zolgensma for spinal muscular atrophy, bringing the company’s total reported tumor cases to nine since the therapy’s 2019 approval. The new disclosures follow advocacy and physician communications that triggered fresh regulatory attention.